11,692 Results

Health Canada approves transfer of Otezla from Celgene Corporation to Amgen Canada.

 Added 18 hours ago

Amgen Canada Inc.announced Health Canada’s approval of the Marketing Authorization transfer of Otezla (apremilast) from Celgene Corporation to Amgen Canada....

Updated positive results for phase III CHECKMATE 214 study of Opdivo + Yervoy versus sunitinib to treat metastatic renal cell carcinoma. - BMS

 Added 18 hours ago

-Bristol-Myers Squibb Company announced updated results from the Phase III CheckMate -214 study evaluating the combination of Opdivo (nivolumab) plus...

Five year positive follow up of CHECKMATE 025 study of Opdivo versus everolimus for metastatic renal cell carcinoma .- BMS

 Added 18 hours ago

Bristol-Myers Squibb Company announced five-year follow-up results from the Phase III CheckMate -025 study, which continue to demonstrate that treatment...

Positive results from phase III VISIBLE 2 trial of subcutaneous Entyvio to treat moderate to severe Crohn's disease.- Takeda

 Added 18 hours ago

-Takeda Pharmaceutical Company Limited announced results from the phase III VISIBLE 2 clinical trial evaluating the efficacy and safety of...

FDA approves Twirla weekly application contraceptive patch.-Agile Therapeutics

 Added 18 hours ago

Agile Therapeutics, Inc., a women’s healthcare company, announced that the FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system....

Chiesi establishes Boston unit to support treatments for rare lysosomal storage, hematological and ophthalmological disorders in the US.

 Added 1 day ago

Chiesi Farmaceutici has established a rare disease unit in Boston. The division will develop treatments for patients with rare lysosomal...

Gantenerumab arm of the phase II/III DIAN-TU-001 study did not meet its primary endpoint for early- onset Alzheimer's disease.- Roche

 Added 1 day ago

Roche has announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in...

Long term data for Epsolay confirms safety profile in rosacea.- Sol-Gel Technologies

 Added 2 days ago

Sol-Gel Technologies announced positive topline data for its open-label, long-term safety study, evaluating Epsolay (microencapsulated benzoyl peroxide cream 5%) in...

NICE in draft guidance does not recommend the combination of Keytruda + Inlyta to treat renal cell carcinoma. Merck Inc.+ Pfizer

 Added 2 days ago

The National Institute for Health and Care Excellence (NICE) has released a draft guidance rejecting MSD’s Keytruda (pembrolizumab) when used...

Interim data from phase IIIb STARDUST study of Stelara shows clinical response in Crohns disease.- J&J Janssen Cilag

 Added 2 days ago

The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim data from the Phase IIIb STARDUST study of Stelara (ustekinumab)...

Load more